BIO-Europe® 2016: Neovacs CEO outlines clinical timeline for lupus drug

November 22, 2016
Miguel Sieler, CEO of 25-year-old French vaccines company Neovacs, chats with Mike Ward, global director of content for Informa Pharma Intelligence, about the company's early lead in immunostimulation research. They discuss upcoming clinical milestones for the company's lead candidate IFNα-Kinoid—a drug targeting systemic lupus erythematosus—and innovative early-stage research Neovacs is pursuing in the Type 1 diabetes space. Founded in 1993 by the famous French immunologist Dr. Daniel Zagury, NeoVacs is a spin-off from the University Pierre et Marie Curie in Paris.
Previous Video
BIO-Europe® 2016: AiCuris seeks partners for antibacterial programs
BIO-Europe® 2016: AiCuris seeks partners for antibacterial programs

AiCuris CEO Holger Zimmermann talks to Mike Ward, global director of content for Informa Pharma Intelligenc...

Next Video
Dr. Holger N. Reithinger
Dr. Holger N. Reithinger

Interview from #BIOEurope 2016 in Cologne: Venture capital firm Forbion with about EUR 700 million under ma...